Q3 25 EPS
$1.07
BEAT +2.21%
Est. $1.05
Q3 25 Revenue
$5.14B
BEAT +1.28%
Est. $5.08B
vs S&P Since Q3 25
-26.4%
TRAILING MARKET
GEHC -21.5% vs S&P +4.8%
Market Reaction
Did GEHC Beat Earnings? Q3 2025 Results
GE HealthCare navigated a tariff-pressured quarter with enough underlying momentum to edge past Wall Street expectations, posting Q3 2025 adjusted EPS of $1.07 against a consensus of $1.05, a beat of 2.21%, while revenue of $5.14 billion climbed 5.8%… Read more GE HealthCare navigated a tariff-pressured quarter with enough underlying momentum to edge past Wall Street expectations, posting Q3 2025 adjusted EPS of $1.07 against a consensus of $1.05, a beat of 2.21%, while revenue of $5.14 billion climbed 5.8% year over year and cleared estimates by 1.28%. The headline story, however, was the toll of trade costs: net income slipped to $446 million, or $0.98 per share, down from $470 million, or $1.02 per share, a year earlier, as tariffs carved out roughly $0.45 per share in adjusted EPS impact for the full year. Management was explicit that absent those headwinds, both margins and earnings would have grown. Bright spots included a 20% revenue surge in Pharmaceutical Diagnostics to $749 million and organic orders growth of 6% across all segments, with a book-to-bill ratio of 1.06x signaling durable demand. Looking ahead, GE HealthCare lifted the lower bound of its full-year adjusted EPS guidance to $4.51 from $4.43, narrowing the range to $4.51 to $4.63, while reaffirming organic revenue growth of approximately 3% and free cash flow of at least $1.4 billion.
Key Takeaways
- • Revenue growth driven by strength in EMEA and the U.S.
- • Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics drove revenue performance
- • Organic orders growth of 6% across all segments
- • Book-to-bill ratio of 1.06x indicating healthy demand
- • Volume and price benefits partially offset tariff impacts
- • Commercial execution leveraging broad portfolio and services
GEHC YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
GEHC Revenue by Segment
With YoY comparisons, source: SEC Filings
“We delivered robust orders with growth across all segments in the third quarter. This was led by customer demand for our differentiated solutions and a healthy capital equipment environment. Revenue performance was driven by Imaging, Advanced Visualization Solutions, and Pharmaceutical Diagnostics, and was ahead of our expectations. We continue to see momentum with commercial execution, where our teams leverage our broad portfolio and services, creating sustainable revenue and strengthening customer relationships. As a result of our increased R&D investments, we are entering a new wave of innovation and, coupled with our focus on lean, we expect to accelerate top and bottom line growth.”
— Peter Arduini, Q3 2025 Earnings Press Release
GEHC Earnings Trends
GEHC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GEHC EPS Trend
Earnings per share: estimate vs actual
GEHC Revenue Trend
Quarterly revenue: estimate vs actual
GEHC Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $0.99 | — | $5.13B | +2.06% |
| Q4 25 BEAT FY | $1.41 | $1.44 | +2.13% | $5.70B | +1.79% |
| FY Full Year | $4.55 | $4.59 | +0.85% | $20.63B | +0.49% |
| Q3 25 BEAT | $1.05 | $1.07 | +2.21% | $5.14B | +1.28% |
| Q2 25 BEAT | $0.92 | $1.06 | +15.51% | $5.01B | +0.84% |
| Q1 25 BEAT | $0.91 | $1.01 | +10.61% | $4.78B | +2.61% |